Graham Capital Management L.P. bought a new stake in Amgen, Inc. (NASDAQ:AMGN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 7,500 shares of the medical research company’s stock, valued at approximately $1,292,000. Amgen makes up 0.0% of Graham Capital Management L.P.’s holdings, making the stock its 29th largest position.

A number of other institutional investors also recently modified their holdings of AMGN. Financial Advisory Service Inc. lifted its holdings in shares of Amgen by 0.3% during the second quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock worth $340,000 after purchasing an additional 5 shares during the period. Jackson Grant Investment Advisers Inc. lifted its holdings in shares of Amgen by 0.8% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after purchasing an additional 5 shares during the period. Capital Advisors Ltd. LLC lifted its holdings in shares of Amgen by 0.6% during the second quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock worth $190,000 after purchasing an additional 7 shares during the period. Ballentine Partners LLC lifted its holdings in shares of Amgen by 0.3% during the second quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock worth $620,000 after purchasing an additional 9 shares during the period. Finally, Hudock Capital Group LLC lifted its holdings in shares of Amgen by 0.5% during the second quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock worth $330,000 after purchasing an additional 10 shares during the period. Hedge funds and other institutional investors own 78.38% of the company’s stock.

A number of equities analysts have recently commented on AMGN shares. BMO Capital Markets reiterated a “market perform” rating and set a $198.00 price target on shares of Amgen in a report on Thursday, October 26th. Cann reiterated a “buy” rating on shares of Amgen in a report on Monday, August 28th. Oppenheimer reiterated a “buy” rating and set a $203.00 price target on shares of Amgen in a report on Thursday, September 7th. Mizuho reiterated a “buy” rating and set a $198.00 price target (up previously from $183.00) on shares of Amgen in a report on Thursday, September 28th. Finally, Zacks Investment Research lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Monday, October 16th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $190.22.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,050 shares of company stock valued at $1,239,673. Insiders own 0.19% of the company’s stock.

Amgen, Inc. (NASDAQ AMGN) opened at $175.41 on Monday. Amgen, Inc. has a 52 week low of $141.00 and a 52 week high of $191.10. The firm has a market cap of $127,330.00, a price-to-earnings ratio of 13.94, a P/E/G ratio of 2.54 and a beta of 1.36. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business had revenue of $5.77 billion during the quarter, compared to the consensus estimate of $5.75 billion. During the same quarter last year, the firm earned $3.02 earnings per share. Amgen’s quarterly revenue was down .7% on a year-over-year basis. analysts expect that Amgen, Inc. will post 12.66 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, December 8th. Shareholders of record on Friday, November 17th were paid a $1.15 dividend. This represents a $4.60 annualized dividend and a yield of 2.62%. The ex-dividend date was Thursday, November 16th. Amgen’s dividend payout ratio (DPR) is currently 41.55%.

Amgen declared that its Board of Directors has initiated a share repurchase plan on Wednesday, October 25th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

ILLEGAL ACTIVITY WARNING: “7,500 Shares in Amgen, Inc. (AMGN) Purchased by Graham Capital Management L.P.” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/7500-shares-in-amgen-inc-amgn-purchased-by-graham-capital-management-l-p/1756755.html.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.